FDA clears Vasomune Therapeutics’ IND for pegevongitide in severe burn resuscitation. Explore what this Tie2 therapy could change for vascular leak treatment.
Can LYMPHIR boost CAR-T therapy success in lymphoma? Discover what early trial data reveals about immune microenvironment targeting.
Azenta acquires UK Biocentre for £20.5M to expand European biorepository capabilities. Discover what this means for life sciences research infrastructure.
Akeso and INOVIO test cadonilimab plus INO-5412 in the INSIGhT glioblastoma trial. Explore what this immunotherapy strategy could mean for GBM research.
Forma Life Sciences launches a U.S. CDMO focused on oral solid drug manufacturing. Discover what the move means for pharma supply chains and drug development.
AN2 Therapeutics plans a Phase 2 trial of epetraborole for polycythemia vera. Explore what this strategy could mean for future hematology treatments.
ARPA-H backs Seaport Therapeutics’ GlyphCele program targeting gut lymphatics in metabolic disease and pancreatic cancer. Read the analysis.
Affinia Therapeutics’ AFTX-201 wins FDA Fast Track for BAG3 cardiomyopathy. Explore what this means for cardiac gene therapy and future heart failure treatments.
Persevere Therapeutics launches misetionamide trial in platinum-resistant ovarian cancer. Discover what this dual-pathway strategy could mean for treatment.
Psyence Biomedical Ltd. advances natural psilocybin therapy in a Phase IIb cancer distress trial. Explore what this means for psychedelic medicine development.